Adial Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07 2021 - 9:00AM
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW)
(“Adial” or the “Company”), a clinical-stage biopharmaceutical
company focused on developing therapies for the treatment and
prevention of addiction and related disorders, today announced that
William Stilley, Chief Executive Officer of Adial Pharmaceuticals,
will be presenting at the H.C. Wainwright 23rd Annual Global
Investment Conference being held virtually between September 13-15,
2021.
Adial Pharmaceutical’s presentation will be
available on-demand to registered attendees via the conference
platform beginning Monday, September 13, 2021 at 7:00 AM Eastern
Time.
The webcast can be accessed here and on the
investor relations section of Adial Pharmaceutical’s website at
https://ir.adialpharma.com/. Management will also be participating
in one-on-one meetings with qualified members of the investor
community throughout the conference.
About Adial Pharmaceuticals,
Inc.
Adial Pharmaceuticals is a clinical-stage
biopharmaceutical company focused on the development of treatments
for addictions. The Company’s lead investigational new drug
product, AD04, is a genetically targeted, serotonin-3 receptor
antagonist, therapeutic agent for the treatment of Alcohol Use
Disorder (AUD) and is currently being investigated in the Company’s
landmark ONWARD™ pivotal Phase 3 clinical trial for the potential
treatment of AUD in subjects with certain target genotypes, which
are to be identified using the Company’s proprietary companion
diagnostic genetic test. A Phase 2b clinical trial of AD04 for the
treatment of AUD showed promising results in reducing frequency of
drinking, quantity of drinking and heavy drinking (all with
statistical significance), and no overt safety concerns (there were
no statistically significant serious adverse events reported). AD04
is also believed to have the potential to treat other addictive
disorders such as Opioid Use Disorder, gambling, and obesity. The
Company is also developing adenosine analogs for the treatment of
pain and other disorders. Additional information is available at
www.adialpharma.com.
Contact:Crescendo Communications, LLC
David Waldman / Natalya RudmanTel:
212-671-1021Email: adil@crescendo-ir.com
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Apr 2023 to Apr 2024